Bolt Biotherapeutics revamps as it drops lead cancer asset, changes CEO and trims headcount
Bolt Biotherapeutics is reshuffling to cut costs and extend its cash runway to the second half of 2026.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
